← Trials/Trial dossier/NCT02063269

UnknownPhase NA

Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles

Differences of Functional Changes in Brain by Rivastigmine According to Butyrylcholinesterase Alleles in Alzheimer's Disease Patients(Rivastigmine, Imaging, and BuChE in AD: RIBA)

Lead sponsor

Seoul National University Hospital

Asset

Rivastigmine

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Alzheimer’s disease

Key I/E criterion

•Alzheimer's disease

Primary endpoints

•Mean changes of Standardized Uptake Values (SUVmean) in PET imaging•Mean changes of serum BuChE activity between BuChE wild type and K-variant type

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDCENA713DKR15T

NCT IDNCT02063269

Timeline

Milestones

Study start2014-02 (month precision)

Study first posted2014-02-14estimated

Last update posted2015-05-14estimated

Primary completion2017-06estimated (month precision)

Study completion2017-06estimated (month precision)

Assets

Drug assets

Rivastigmine

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Clinical diagnosis of Alzheimer's Disease (NINCD-ADRDA and MMSE between 10 ~26)

•Who didn't take Cholinesterase Inhibitor on liver within 3 months

Exclusion criteria

•diagnosed with diseases other than AD that affect brain atrophy according to Brain MRI

•Diagnosed with diseases other than AD which affect cognitive functions (i.g. Schizophrenia, Major Depression, Mental Retardation, encephalopathy, etc.)

•Didn't suspect of drug or alcohol addictions within last decade

•Unable to participate the study due to poor sight and hearing

•Who aren't suitable to participate according to the researchers' judgement

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition

Neuroimaging

Function / daily living

Behavior / neuropsychiatric

Other (unclassified)

Global cognition

3 endpoints

Secondary/protocol endpoint

the cognitive changes in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)

Time frame:screening, 26, and 52 weeks (3 times)

ADAS-Cog

descriptive

Secondary/protocol endpoint

the cognitive changes in Mini-Mental State Exam (MMSE)

Time frame:screening, 26, and 52 weeks (3 times)

Mini-Mental State Examination (MMSE)

descriptive

Secondary/protocol endpoint

the disease severity changes by Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) between BuChE wild type and K-variant type

Time frame:screening, 26, and 52 weeks (3 times)

Clinical Dementia Rating-Sum of Boxes (CDR-SB)

descriptive

Function / daily living

1 endpoint

Secondary/protocol endpoint

the daily function changes by Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)

Time frame:screening, 26, and 52 weeks (3 times)

ADCS-Activities of Daily Living (ADCS-ADL)

descriptive

Behavior / neuropsychiatric

1 endpoint

Secondary/protocol endpoint

the behavioural changes by Caregiver-Administered Neuropsychiatric Inventory (NPI)

Time frame:screening, 26, and 52 weeks (3 times)

Neuropsychiatric Inventory (NPI)

descriptive

Neuroimaging

2 endpoints

Primary/protocol endpoint

the mean changes of Standardized Uptake Values (SUVmean) in PET imaging

Time frame:screening and 52weeks (2 times)

descriptive

Secondary/protocol endpoint

the mean changes of cortical thickness in brain MRI

Time frame:screening and 52weeks (2 times)

descriptive

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

the mean changes of serum BuChE activity between BuChE wild type and K-variant type

Time frame:screening and 52weeks (2 times)

descriptive

Publications (15)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.